Variables | Values |
---|---|
Female gender, n (%) | 70 (50.4%) |
Age (yrs), mean ± SD | 67.2 ± 15.9 |
Comorbid conditions, n (%) | 131 (94.2%) |
 Diabetes mellitus | 53 (38.1%) |
 Cardiovascular diseases | 41 (29.5%) |
 Renal diseases | 37 (26.6%) |
 Cerebrovascular diseases | 35 (25.2%) |
 Solid malignancy | 21 (15.1%) |
 Chronic pulmonary diseases | 20 (14.3%) |
 Hematologic malignancy | 16 (11.5%) |
 Liver diseases | 10 (7.2%) |
 Organ transplantation | 4 (2.9%) |
 HIV infection | 2 (1.4%) |
Previous hospitalization within 3Â months, n (%) | 73 (52.5%) |
Site of infection in 139 patients at enrollment, n (%) | |
 Lower respiratory tract infection | 93 (66.9%) |
 Blood stream infection | 40 (28.8%) |
 Urinary tract infection | 18 (12.9%) |
 Gastrointestinal tract infection | 11 (7.9%) |
 Skin and soft tissue infection | 8 (5.8%) |
 Surgical site infection | 1 (0.7%) |
 Bone and joint infection | 1 (0.7%) |
Documented bacteria-caused infections in 110 patients that required colistin therapy, n (%) | |
 A. baumannii | 79 (71.8%) |
 K. pneumoniae | 18 (16.4%) |
 P. aeruginosa | 9 (8.2%) |
 E. coli | 2 (1.8%) |
 E. cloacae | 2 (1.8%) |
Medical procedure, n (%) | |
 Mechanical ventilation | 117 (84.2%) |
 Central venous catheterization | 85 (61.2%) |
 Chronic intermittent hemodialysis | 53 (38.1%) |
Severity of patient illness, mean ± SD | |
 APACHE II score at enrollment | 21.8 ± 7.4 |
Antibiotic use for the current hospitalization prior to study enrollment, n (%) | 134 (96.4%) |
 Carbapenems | 112 (80.6%) |
 Cephalosporins | 56 (40.3%) |
 Beta-lactam/beta-lactamase inhibitors | 75 (54.0%) |
 Fluoroquinolones | 39 (28.1%) |
 Vancomycin | 43 (30.9%) |
 Aminoglycosides | 6 (4.3%) |
 Colistin | 9 (6.8%) |
Colistin use within 3Â months prior to study enrollment, n (%) | 15 (10.8%) |